Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2025)

Ultragenyx Pharmaceutical has reported Work In Process over the past 9 years, most recently at $27.0 million for Q4 2025.

  • Quarterly Work In Process rose 22.73% to $27.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.0 million through Dec 2025, up 22.73% year-over-year, with the annual reading at $27.0 million for FY2025, 22.73% up from the prior year.
  • Work In Process was $27.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $29.2 million in the prior quarter.
  • Over five years, Work In Process peaked at $29.2 million in Q3 2025 and troughed at $6.8 million in Q1 2021.
  • The 5-year median for Work In Process is $18.7 million (2023), against an average of $17.9 million.
  • Year-over-year, Work In Process soared 76.75% in 2022 and then dropped 21.77% in 2025.
  • A 5-year view of Work In Process shows it stood at $10.5 million in 2021, then skyrocketed by 66.47% to $17.5 million in 2022, then increased by 7.85% to $18.9 million in 2023, then grew by 16.66% to $22.0 million in 2024, then increased by 22.73% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Work In Process are $27.0 million (Q4 2025), $29.2 million (Q3 2025), and $19.8 million (Q2 2025).